Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
CD19 CAR T-cell treatment effective in B-cell lymphoma relapse after allogeneic HSCT
Key clinical point: CAR T cell treatment from recipient-derived leukapheresis products after a prior alloHCT appears effective and safe in patients with B-cell lymphoma.
Major finding: Overall, 6 of 8 (75%) of the patients responded.
Study details: A single center retrospective analysis, course and outcome of all allografted patients treated with CD19 CAR constructs for B-cell lymphoma between Oct. 2018 and Nov.
Disclosures: Several of the authors received funding from a variety of pharmaceutical companies.
Citation:
First author et al. Biology of Blood and Marrow Transplantation. 2020; doi.org/10.1016/j.bbmt.2020.04.025.